Precision Cancer Diagnostics
Precision Cancer Diagnostics
Geneseq Biosciences designs, validates, and launches pioneering genomic cancer tests, distributed globally through licensing and partnerships.
Validated microRNA classifier that assists diagnosis in ambiguous melanocytic lesions. End-to-end Australian development with audit-ready pipelines and clear reports.
A minimally invasive blood test that measures melanoma-specific microRNA patterns to aid in early detection, disease monitoring, and treatment planning.
Toolkit for transforming histopathology reports into prognostic assessments, including diagnostic ambiguity detection and strategic treatment summaries.
Larger, multi-indication diagnostic assay, building on patented Melaseq technology.
Scalable next-generation microRNA analysis platform for early cancer detection, with class-leading accuracy and data trasparency, at a price point that enables broad access.
| Year | Title | Journal | Link |
|---|---|---|---|
| 2024 | RNA-seq validation of microRNA expression signatures for precision melanoma diagnosis and prognostic stratification | BMC Medical Genomics | View |
| 2023 | Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma | British Journal of Dermatology | View |
| 2023 | Liquid biopsy test for Australia’s National Cancer, clinical validation poster | AACR Annual Meeting | View |
| 2021 | Translation of a circulating miRNA signature of melanoma to tissue | Biomarkers in Medicine | View |
| 2019 | Characterisation and validation of Mel38; a multi-tissue microRNA signature of cutaneous melanoma | PLOS ONE | View |
| 2018 | Circulating microRNA biomarkers in melanoma | Biomolecules | View |
| 2019 | A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response | Melanoma Research | View |
| 2018 | Development and validation of a plasma-based melanoma biomarker (MEL38) | British Journal of Cancer | View |
Family of patents protecting core microRNA diagnostic technology.
Australia
Japan
United States
South Korea
Europe
Canada
ChinaSource: WO2019068139A1 and national phase entries.
Geneseq is a Melbourne-based genomics company focused on microRNA diagnostics for cancer. We combine international experience in IVD assay design, with scalable bioinformatics, and regulatory know-how to turn ideas into clinically actionable results.
